Perrigo Company plc (NYSE:PRGO - Get Free Report) has earned a consensus rating of "Hold" from the six brokerages that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and one has given a buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $19.3333.
Several research analysts have commented on the stock. Wall Street Zen upgraded shares of Perrigo from a "hold" rating to a "buy" rating in a research report on Saturday, August 8th. Weiss Ratings upgraded Perrigo from a "sell (d-)" rating to a "sell (d)" rating in a research report on Thursday, August 6th. Finally, Zacks Research upgraded shares of Perrigo from a "strong sell" rating to a "hold" rating in a research note on Monday, April 27th.
View Our Latest Stock Analysis on Perrigo
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in PRGO. California State Teachers Retirement System raised its position in Perrigo by 911.0% during the second quarter. California State Teachers Retirement System now owns 1,617,661 shares of the company's stock valued at $155,694,000 after purchasing an additional 1,457,656 shares in the last quarter. HB Wealth Management LLC bought a new position in shares of Perrigo during the 2nd quarter valued at about $211,000. Odyssean LLC lifted its position in Perrigo by 132.7% in the 2nd quarter. Odyssean LLC now owns 44,334 shares of the company's stock worth $461,000 after buying an additional 25,282 shares during the last quarter. Syon Capital LLC purchased a new stake in Perrigo in the second quarter worth approximately $160,000. Finally, Parvin Asset Management LLC bought a new position in Perrigo during the second quarter valued at approximately $79,000. 95.91% of the stock is currently owned by hedge funds and other institutional investors.
Perrigo Price Performance
PRGO traded down $0.06 on Monday, hitting $14.19. 119,048 shares of the stock were exchanged, compared to its average volume of 3,141,171. The firm has a market capitalization of $1.97 billion, a price-to-earnings ratio of -1.13, a PEG ratio of 1.62 and a beta of 0.51. The company has a debt-to-equity ratio of 1.31, a current ratio of 2.32 and a quick ratio of 1.32. Perrigo has a 12 month low of $9.23 and a 12 month high of $24.49. The business has a 50-day moving average of $11.07 and a two-hundred day moving average of $11.42.
Perrigo (NYSE:PRGO - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $0.50 EPS for the quarter, beating the consensus estimate of $0.39 by $0.11. Perrigo had a negative net margin of 41.85% and a positive return on equity of 11.25%. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same period last year, the firm earned ($0.06) EPS. The business's quarterly revenue was down 3.1% compared to the same quarter last year. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Sell-side analysts forecast that Perrigo will post 2.2 EPS for the current fiscal year.
Perrigo Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Friday, August 28th will be issued a $0.29 dividend. The ex-dividend date of this dividend is Friday, August 28th. This represents a $1.16 dividend on an annualized basis and a dividend yield of 8.2%. Perrigo's dividend payout ratio is presently -9.27%.
Perrigo Company Profile
(
Get Free Report)
Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo's focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.
Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo's operations span research and development, manufacturing, quality assurance and global distribution.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Perrigo, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Perrigo wasn't on the list.
While Perrigo currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.